Expertise in
14
conditions

Dr. John M. Timmerman

Hematology | Oncology
Ronald Reagan UCLA Medical Center
757 Westwood Plz, 
Los Angeles, CA 
Offers Telehealth
Expertise in
14
conditions
Ronald Reagan UCLA Medical Center
757 Westwood Plz, 
Los Angeles, CA 

Overview

John Timmerman is a Hematologist and an Oncologist practicing medicine in Los Angeles, California.

Dr. Timmerman is highly rated in 14 conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, Classical Hodgkin Lymphoma, Hodgkin Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration.

He is actively involved in clinical research, co-authoring 57 peer reviewed articles and participating in 8 clinical trials.

Specialties

Hematology
Oncology

Licenses

Internal Medicine in CA

Hospital Affiliations

Ronald Reagan UCLA Medical Center
Santa Monica - UCLA Med Ctr & Orthopaedic Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 2 Less Insurance Carriers -

Locations

Ronald Reagan UCLA Medical Center
757 Westwood Plz, Los Angeles, CA 90095

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-X19 in Subjects With Relapsed/Refractory Mantle Cell Lymphoma
A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-X19 in Subjects With Relapsed/Refractory Mantle Cell Lymphoma
Enrollment Status: Completed
Publish Date: March 18, 2026
Intervention Type: Drug, Biological
Study Drugs: Brexucabtagene Autoleucel, Cyclophosphamide, Fludarabine, Axicabtagene Ciloleucel
Study Phase: Phase 2
IL-1 Receptor Antagonist to Prevent Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome
IL-1 Receptor Antagonist to Prevent Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome
Enrollment Status: Terminated
Publish Date: February 27, 2026
Intervention Type: Drug, Biological
Study Drugs: Anakinra, Axicabtagene Ciloleucel, Cyclophosphamide, Fludarabine, Fludarabine Phosphate
Study Phase: Phase 2
A Phase 2 Front-Line PET/CT-2 Response-Adapted Brentuximab Vedotin and Nivolumab Incorporated and Radiation-Free Management of Early Stage Classical Hodgkin Lymphoma (cHL)
A Phase 2 Front-Line PET/CT-2 Response-Adapted Brentuximab Vedotin and Nivolumab Incorporated and Radiation-Free Management of Early Stage Classical Hodgkin Lymphoma (cHL)
Enrollment Status: Active_not_recruiting
Publish Date: November 06, 2024
Intervention Type: Other, Drug, Biological
Study Drugs: Bleomycin, Brentuximab, Dacarbazine, Doxorubicin, Nivolumab, Vinblastine
Study Phase: Phase 2
A Phase 1/2 Multi-center Study Evaluating the Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Utomilumab in Subjects With Relapsed/Refractory Large B-Cell Lymphoma
A Phase 1/2 Multi-center Study Evaluating the Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Utomilumab in Subjects With Relapsed/Refractory Large B-Cell Lymphoma
Enrollment Status: Terminated
Publish Date: June 28, 2024
Intervention Type: Biological, Drug
Study Drugs: Cyclophosphamide, Fludarabine, Axicabtagene Ciloleucel, Utomilumab
Study Phase: Phase 1
A Phase 1, Open-Label, Extension Study of Multiple Intravenous Doses of IGN002 Administered Weekly to Subjects With Refractory Non-Hodgkin Lymphoma (NHL)
A Phase 1, Open-Label, Extension Study of Multiple Intravenous Doses of IGN002 Administered Weekly to Subjects With Refractory Non-Hodgkin Lymphoma (NHL)
Enrollment Status: Withdrawn
Publish Date: March 11, 2022
Intervention Type: Biological
Study Phase: Phase 1
A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Intravenous Doses of IGN002 Administered Weekly to Subjects With Refractory Non-Hodgkin Lymphoma (NHL)
A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Intravenous Doses of IGN002 Administered Weekly to Subjects With Refractory Non-Hodgkin Lymphoma (NHL)
Enrollment Status: Terminated
Publish Date: March 11, 2022
Intervention Type: Biological
Study Drug: IGN002 Monoclonal Antibody Fusion Protein
Study Phase: Phase 1
A Phase I/IB Study of Ipilimumab or Nivolumab in Patients With Relapsed Hematologic Malignancies After Allogeneic Hematopoietic Cell Transplantation
A Phase I/IB Study of Ipilimumab or Nivolumab in Patients With Relapsed Hematologic Malignancies After Allogeneic Hematopoietic Cell Transplantation
Enrollment Status: Completed
Publish Date: June 24, 2021
Intervention Type: Biological, Other
Study Phase: Phase 1
View 6 Less Clinical Trials

57 Total Publications

Impact of clonal hematopoiesis of indeterminate potential on treatment outcomes in multiple myeloma patients undergoing CAR-T cell therapy.
Impact of clonal hematopoiesis of indeterminate potential on treatment outcomes in multiple myeloma patients undergoing CAR-T cell therapy.
Journal: International journal of hematology
Published: April 14, 2026
Similar Doctors
Expertise in
11
conditions
Dr. Thomas D. Coates
Hematology | Oncology
Expertise in
11
conditions
Dr. Thomas D. Coates
Hematology | Oncology
Referral may be required

Office

4650 W Sunset Blvd # 54, 
Los Angeles, CA 
 (9.1 miles away)
323-361-4624
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Thomas Coates is a Hematologist and an Oncologist practicing medicine in Los Angeles, California. Dr. Coates is highly rated in 11 conditions, according to our data. His clinical expertise encompasses Hemoglobinopathy, Anemia, Congenital Hemolytic Anemia, Splenectomy, and Bone Marrow Transplant.

Expertise in
31
conditions
Dr. Arun S. Singh
Hematology | Oncology
Expertise in
31
conditions
Dr. Arun S. Singh
Hematology | Oncology
Referral may be required

Sandra Fallon M.D. Inc.

2020 Santa Monica Blvd Ste 580, 
Santa Monica, CA 
 (3.2 miles away)
310-829-5471
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Arun Singh is a Hematologist and an Oncologist practicing medicine in Santa Monica, California. Dr. Singh is highly rated in 31 conditions, according to our data. His clinical expertise encompasses Adult Soft Tissue Sarcoma, Liposarcoma, Ewing Sarcoma, Tissue Biopsy, and Bone Marrow Aspiration.

Expertise in
55
conditions
Dr. Stephen J. Forman
Hematology | Oncology
Expertise in
55
conditions
Dr. Stephen J. Forman
Hematology | Oncology
Referral may be required

City Of Hope Comprehensive Cancer Center-Duarte

1500 Duarte Rd, 
Duarte, CA 
 (27.5 miles away)
888-304-3959
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Stephen Forman is a Hematologist and an Oncologist practicing medicine in Duarte, California. Dr. Forman is highly rated in 55 conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, Acute Myeloid Leukemia (AML), Graft Versus Host Disease (GvHD), Bone Marrow Transplant, and Bone Marrow Aspiration.

Frequently Asked Questions about Dr. John M. Timmerman

How do I make an appointment with Dr. John M. Timmerman?

You can book an appointment with Dr. John M. Timmerman by calling their office at 310-267-9643. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. John M. Timmerman a top-rated expert for Non-Hodgkin Lymphoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. John M. Timmerman is classified as an Elite expert for Non-Hodgkin Lymphoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. John M. Timmerman specialize in?

While Dr. John M. Timmerman is a Hematology, they have specific expertise in Non-Hodgkin Lymphoma, Classical Hodgkin Lymphoma, and Hodgkin Lymphoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. John M. Timmerman participate in research or clinical trials?

Yes. Dr. John M. Timmerman has published 57 articles and abstracts on conditions like Non-Hodgkin Lymphoma. You can view a list of Dr. John M. Timmerman's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. John M. Timmerman accept my insurance?

Dr. John M. Timmerman accepts most major insurance plans, including Aetna and Blue Cross Blue Shield. We recommend calling the office directly at 310-267-9643 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Timmerman's expertise for a condition
ConditionClose
View All 7 Advanced Conditions
View All 24 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile